ABOS Acumen Pharmaceuticals, Inc. Stock Quote

ABOS [NASD]

Index	-	P/E	-	EPS (ttm)	-2.33	Insider Own	15.73%	Shs Outstand	40.47M	Perf Week	6.81%
Market Cap	139.28M	Forward P/E	-	EPS next Y	-0.98	Insider Trans	0.00%	Shs Float	34.12M	Perf Month	-16.06%
Income	-82.70M	PEG	-	EPS next Q	-0.26	Inst Own	77.90%	Short Float	5.56%	Perf Quarter	-39.47%
Sales	-	P/S	-	EPS this Y	32.00%	Inst Trans	5.24%	Short Ratio	8.19	Perf Half Y	-65.01%
Book/sh	5.34	P/B	0.65	EPS next Y	-47.00%	ROA	-43.60%	Target Price	17.50	Perf Year	-
Cash/sh	4.68	P/C	0.74	EPS next 5Y	32.10%	ROE	-58.20%	52W Range	3.02 - 26.98	Perf YTD	-48.96%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-87.21%	Beta	-
Dividend %	-	Quick Ratio	48.80	Sales past 5Y	-	Gross Margin	-	52W Low	14.24%	ATR	0.31
Employees	14	Current Ratio	48.80	Sales Q/Q	-	Oper. Margin	-	RSI (14)	43.02	Volatility	8.04% 9.55%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	67.70%	Profit Margin	-	Rel Volume	0.80	Prev Close	3.48
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 16 AMC	Payout	-	Avg Volume	231.36K	Price	3.45
Recom	1.50	SMA20	-5.69%	SMA50	-18.99%	SMA200	-61.79%	Volume	184,871	Change	-0.86%

Jan-21-22

Upgrade

BofA Securities

Neutral → Buy

$16 → $14

Jul-26-21

Initiated

UBS

Buy

$27

Jul-26-21

Initiated

Stifel

Buy

$27

Jul-26-21

Initiated

Credit Suisse

Outperform

$26

Jul-26-21

Initiated

BofA Securities

Neutral

$20

May-16-22 10:00PM	Acumen Pharmaceuticals, Inc. (ABOS) Q1 2022 Earnings Call Transcript Motley Fool
04:05PM	Acumen Pharmaceuticals Reports Financial Results for First Quarter 2022 and Business Highlights GlobeNewswire
May-11-22 05:08PM	Acumen Pharmaceuticals to Report First Quarter 2022 Financial Results on May 16, 2022 GlobeNewswire -14.21%
Apr-27-22 08:00AM	Comprehensive Analysis in Frontiers in Neuroscience Highlights Acumen Pharmaceuticals New Approach to Treating Alzheimer's Disease GlobeNewswire
Apr-02-22 12:00AM	Acumen Pharmaceuticals, Inc. (ABOS) Q4 2021 Earnings Call Transcript Motley Fool
Apr-01-22 05:01PM	We're Hopeful That Acumen Pharmaceuticals (NASDAQ:ABOS) Will Use Its Cash Wisely Simply Wall St.
Mar-28-22 04:05PM	Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2021 and Business Highlights GlobeNewswire -9.34%
Mar-16-22 04:15PM	Acumen Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on March 28, 2022 GlobeNewswire +11.72%
Dec-30-21 04:16AM	Bullish Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) insiders filled their treasuries with US$5.7m worth of stock over last year Simply Wall St.
Nov-25-21 07:35AM	15 Pharmaceutical Stocks to Buy According to Peter Kolchinskys RA Capital Insider Monkey
Nov-15-21 08:00AM	Acumen Pharmaceuticals Reports Financial Results for Third Quarter 2021 and Business Highlights GlobeNewswire -8.49%
Nov-08-21 08:00AM	Acumen Pharmaceuticals to Present at Upcoming Investor Conferences GlobeNewswire
Nov-02-21 08:00AM	Acumen Pharmaceuticals to Present Clinical Trial Design for INTERCEPT-AD, the Phase 1 Placebo-Controlled, Single- and Multiple-Dose Clinical Trial of ACU193, at 2021 Clinical Trials on Alzheimers Disease (CTAD) Conference GlobeNewswire
Oct-07-21 08:00AM	Acumen Announces First Patient Dosed in a Phase 1 Clinical Trial of ACU193, a Monoclonal Antibody that Selectively Targets Toxic A Oligomers for the Treatment of Early Alzheimers Disease GlobeNewswire
Oct-01-21 06:05AM	Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth Simply Wall St.
Aug-16-21 04:05PM	Acumen Pharmaceuticals Reports Financial Results for Second Quarter 2021 and Business Highlights GlobeNewswire
Jul-23-21 07:13PM	Landmark Infrastructure, CVRx See Activist Action Barrons.com
Jul-01-21 05:02PM	Krispy Kreme IPO Gains Nearly 24% in Busy Week for Deals Barrons.com
11:14AM	Acumen Pharmaceuticals shares soar 25% in trading debut MarketWatch
Jun-30-21 10:44PM	Acumen Pharmaceuticals Announces Pricing of Upsized Initial Public Offering GlobeNewswire

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
OConnell Daniel Joseph	President and CEO	Nov 30	Option Exercise	4.47	1,118	4,997	2,685	Dec 02 04:41 PM
Manning Paul B	10% Owner	Jul 06	Buy	16.00	312,500	5,000,000	3,352,693	Jul 08 06:35 PM
Stalfort John A III	Director	Jul 06	Buy	16.00	35,000	560,000	172,324	Jul 08 06:17 PM
Hardie Robert D.	10% Owner	Jul 06	Buy	16.00	312,500	5,000,000	3,352,693	Jul 08 06:15 PM
Hardie Robert D.	10% Owner	Jul 06	Buy	16.00	750,000	12,000,000	3,951,156	Jul 08 06:14 PM
Fountain Nathan B	Director	Jul 06	Buy	16.00	6,250	100,000	6,250	Jul 08 06:13 PM
Sands Capital Ventures Discove	10% Owner	Jul 06	Buy	14.88	450,000	6,696,000	3,417,075	Jul 08 05:21 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Jul 06	Buy	16.00	1,875,000	30,000,000	7,881,889	Jul 08 04:32 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience